Table 2. Change in seizure frequency with each treatment modality.
| Response to treatment with CBMPs | Maximum titrated therapy ( n = 35) |
CBD isolate ( n = 19) |
CBD broad spectrum ( n = 17) |
CBD & Δ
9
-THC
( n = 17) |
p -Value |
|---|---|---|---|---|---|
| ≥50% reduction in seizure frequency | 23 (65.7%) [95% CI: 47.8–80.9%] |
6 (31.6%) [95% CI: 12.6–56.6%] |
3 (17.6%) [95% CI: 3.8–43.4%] |
16 (94.1%) [95% CI: 71.3–99.9%] |
<0.001 |
| ≥90% reduction in seizure frequency | 13 (37.1%) [95% CI: 21.5–55.1%] |
3 (15.8%) [95% CI: 3.4–39.6%] |
3 (17.6%) [95% CI: 3.8–43.4%] |
9 (52.9%) [95% CI: 27.8–77.0%] |
0.023 |
| Remission | 4 (11.4%) [95% CI: 3.2–26.7%] |
1 (5.3%) [95% CI: 0.1–26.0%] |
0 (0.0%) [95% CI: 0.0–19.5%] |
3 (17.6%) [95% CI: 3.8–43.4%] |
0.134 |
Abbreviations: 95% CI, 95% confidence interval; CBD, cannabidiol; CBMPs, cannabis-based medicinal products; Δ 9 -THC, delta-9-tetrahydrocannabinol